• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺量测定时机可能影响囊性纤维化肺部恶化的住院时间。

Timing of Spirometry May Impact Hospital Length of Stay for Cystic Fibrosis Pulmonary Exacerbation.

机构信息

Nationwide Children's Hospital Center for the Epidemiological Study of Organ Failure and Transplantation, The Ohio State University College of Medicine, Columbus, OH, USA.

Section of Pulmonary Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.

出版信息

Lung. 2018 Apr;196(2):207-211. doi: 10.1007/s00408-018-0082-1. Epub 2018 Jan 18.

DOI:10.1007/s00408-018-0082-1
PMID:29349537
Abstract

PURPOSE

The optimal timing of spirometry during hospitalization for acute pulmonary exacerbation (PEx) in patients with cystic fibrosis (CF) is unclear. We retrospectively evaluated whether measuring spirometry earlier during hospitalization was associated with a shorter length of stay (LOS).

METHODS

In this retrospective study, we analyzed data from the electronic medical record of CF patients 6 years of age and older admitted to a single center for acute PEx requiring IV antibiotic therapy between 2009 and 2016. After excluding patient encounters with missing data on covariates, random-effects linear regression was used to predict LOS as a function of days to first pulmonary function testing (PFT), which was spirometry for our study.

RESULTS

One thousand thirty-five hospitalizations of 242 patients met inclusion criteria, with 801 including complete data on covariates. Mean LOS was 10 ± 7 days, with mean time to first PFT of 4 ± 3 days after admission. In multivariable analysis, each additional day to first PFT was associated with 0.97 days longer LOS (95% CI 0.29, 1.64; p = 0.005).

CONCLUSIONS

As CF researchers and clinicians work to improve management of PEx, the timing of spirometry during hospitalization remains an important question. Obtaining objective lung function data earlier during the course of therapy may provide information which can lead to reduced hospital LOS for PEx.

摘要

目的

在囊性纤维化(CF)患者因急性肺部恶化(PEx)住院期间,进行肺功能检查的最佳时机尚不清楚。我们回顾性评估了住院期间更早进行肺功能检查是否与住院时间更短相关。

方法

在这项回顾性研究中,我们分析了 2009 年至 2016 年间因需要静脉注射抗生素治疗急性 PEx 而入住单一中心的年龄在 6 岁及以上的 CF 患者的电子病历数据。在排除了协变量缺失数据的患者就诊后,我们使用随机效应线性回归来预测住院时间,其因变量为首次肺功能测试(PFT)与入院后的天数,而我们的研究则是将其作为肺功能检查。

结果

242 名患者的 1035 次住院符合纳入标准,其中 801 次住院包含了协变量的完整数据。平均住院时间为 10±7 天,首次 PFT 的平均时间为入院后 4±3 天。在多变量分析中,首次 PFT 每增加一天,住院时间延长 0.97 天(95%CI 0.29,1.64;p=0.005)。

结论

随着 CF 研究人员和临床医生努力改善 PEx 的管理,住院期间肺功能检查的时机仍然是一个重要的问题。在治疗过程中更早获得客观的肺功能数据可能会提供相关信息,从而减少 PEx 的住院时间。

相似文献

1
Timing of Spirometry May Impact Hospital Length of Stay for Cystic Fibrosis Pulmonary Exacerbation.肺量测定时机可能影响囊性纤维化肺部恶化的住院时间。
Lung. 2018 Apr;196(2):207-211. doi: 10.1007/s00408-018-0082-1. Epub 2018 Jan 18.
2
Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.囊性纤维化肺部加重期肺活量测定的可重复性。
Pediatr Pulmonol. 2008 Nov;43(11):1142-1146. doi: 10.1002/ppul.20924.
3
Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.纵向队列研究中婴幼儿囊性纤维化患者肺部加重与临床结局的关系。
BMC Pulm Med. 2017 Dec 11;17(1):188. doi: 10.1186/s12890-017-0546-8.
4
Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.囊性纤维化肺部加重期恢复不佳与长期预后不良相关。
Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.
5
Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.C反应蛋白在预测囊性纤维化肺部加重期治疗反应中的临床应用
PLoS One. 2017 Feb 8;12(2):e0171229. doi: 10.1371/journal.pone.0171229. eCollection 2017.
6
Spirometry use in children hospitalized with asthma.肺活量测定法在哮喘住院儿童中的应用。
Pediatr Pulmonol. 2014 May;49(5):451-7. doi: 10.1002/ppul.22854. Epub 2013 Sep 2.
7
Home-spirometry exacerbation profiles in children with cystic fibrosis.囊性纤维化患儿的家庭肺量计检查加重情况
Pediatr Pulmonol. 2024 Mar;59(3):552-561. doi: 10.1002/ppul.26781. Epub 2023 Nov 28.
8
The Value of Measuring Inspiratory Capacity in Subjects With Cystic Fibrosis.测量囊性纤维化患者吸气容量的价值。
Respir Care. 2018 Aug;63(8):981-987. doi: 10.4187/respcare.05920. Epub 2018 Jul 17.
9
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.囊性纤维化患者肺部病情加重时,静脉注射抗生素治疗持续时间和部位与30天内再次进行静脉注射抗生素治疗的概率相关。
J Cyst Fibros. 2016 Nov;15(6):783-790. doi: 10.1016/j.jcf.2016.04.005. Epub 2016 Apr 29.
10
Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.住院囊性纤维化肺部急性加重的特征描述
Pediatrics. 2017 Feb;139(2). doi: 10.1542/peds.2016-2642.

引用本文的文献

1
The effect of modulators on lung function following inpatient treatment for CF exacerbations.调节剂对囊性纤维化急性加重期住院治疗后肺功能的影响。
Front Pediatr. 2025 Aug 21;13:1654122. doi: 10.3389/fped.2025.1654122. eCollection 2025.

本文引用的文献

1
Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.住院囊性纤维化肺部急性加重的特征描述
Pediatrics. 2017 Feb;139(2). doi: 10.1542/peds.2016-2642.
2
Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.美国囊性纤维化患者肺部加重的频率及费用
Curr Med Res Opin. 2017 Apr;33(4):667-674. doi: 10.1080/03007995.2016.1277196. Epub 2017 Feb 9.
3
Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis.
肺部加重期和肺功能对囊性纤维化患者一般健康相关生活质量的影响。
Health Qual Life Outcomes. 2016 Apr 21;14:63. doi: 10.1186/s12955-016-0465-z.
4
Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.对患有囊性纤维化且肺部病情加重的患者使用抗生素治疗洋葱伯克霍尔德菌复合体。
Cochrane Database Syst Rev. 2016 Jan 20;2016(1):CD009529. doi: 10.1002/14651858.CD009529.pub3.
5
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.囊性纤维化患者肺部加重期治疗的短期和长期反应
Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.
6
Duration of intravenous antibiotic therapy in people with cystic fibrosis.囊性纤维化患者静脉用抗生素治疗的疗程
Cochrane Database Syst Rev. 2013 May 31(5):CD006682. doi: 10.1002/14651858.CD006682.pub4.
7
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.了解囊性纤维化护理的成本:按年龄和健康状况分析。
Value Health. 2013 Mar-Apr;16(2):345-55. doi: 10.1016/j.jval.2012.12.003.
8
Managing treatment complexity in cystic fibrosis: challenges and opportunities.管理囊性纤维化治疗的复杂性:挑战与机遇。
Pediatr Pulmonol. 2012 Jun;47(6):523-33. doi: 10.1002/ppul.22546. Epub 2012 Mar 29.
9
Complications associated with peripheral or central routes for central venous cannulation.与中心静脉置管的外周或中央途径相关的并发症。
Anaesthesia. 2012 Jan;67(1):65-71. doi: 10.1111/j.1365-2044.2011.06911.x. Epub 2011 Oct 4.
10
Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007.2001-2007 年私营保险囊性纤维化(CF)患者医疗费用的全国趋势。
Pediatr Pulmonol. 2011 Aug;46(8):770-6. doi: 10.1002/ppul.21441. Epub 2011 Apr 4.